Abstract:Background and objective: The motivation behind cancer subtyping is to identify subgroups of cancer patients with distinguishable phenotypes of clinical importance. It can assist in advancement of subtype-targeted based treatments. Subtype identification is a complicated task, therefore requires multi-omics data integration to identify the precise patients' subgroup. Over the years, several computational attempts have been made to identify the cancer subtypes accurately using integrative multi-omics analysis. Some studies have used Autoencoders (AE) to capture multi-omics feature integration in lower dimensions for identifying subtypes in specific types of cancer. However, capturing the highly informative latent space by learning the deep architectures of AE to attain a satisfactory generalized performance is required. Therefore, in this study, a novel AE-assisted cancer subtyping framework is presented that utilizes the compressed latent space of a Sparse AE neural network for multi-omics clustering. Methods: The proposed framework first performs a supervised feature selection based on the survival status of the patients. The selected features from each of the omic data are passed to the AE. The information embedded in the latent space of the trained AE neural networks are then used for cancer subtyping using Spectral clustering. The AE architecture designed in this study exhaustively searches the best compression for multi-omics data by varying the number of neurons in the hidden layers and penalizing activations within the layers. Results and conclusion: The proposed framework is applied to five different multi-omics cancer datasets taken from The Cancer Genome Atlas. It is observed that for getting a robust information bottleneck, a compression of 10-20% of the input features along with an L1 regularization penalty of 0.01 or 0.001 performs well for most of the cancer datasets. Clustering performed on this latent representation generates clusters with better silhouette scores and significantly varying survival patterns. For further biological assessment, differential expression analysis is performed between the identified subtypes of Glioblastoma multiforme (GBM), followed by enrichment analysis of the differentially expressed biomarkers. Several pathways and disease ontology terms coherent to GBM are found to be significantly associated. Varying responses of the identified GBM subtypes towards the drug Temozolomide is also tested to demonstrate its clinical importance. Hence, the study shows that AE-assisted multi-omics integration can be used for the prediction of clinically significant cancer subtypes.

MoVAE: Multi-Omics Variational Auto-Encoder for Cancer Subtype Detection

Integrated multi-omics analysis of ovarian cancer using variational autoencoders

MCluster-VAEs: an End-to-end Variational Deep Learning-Based Clustering Method for Subtype Discovery Using Multi-Omics Data.

Integrated Multi-omics Analysis Using Variational Autoencoders: Application to Pan-cancer Classification

Integrate multi-omics data with biological interaction networks using Multi-view Factorization AutoEncoder (MAE)

Novel multi-omics deconfounding variational autoencoders can obtain meaningful disease subtyping

MoGCN: A Multi-Omics Integration Method Based on Graph Convolutional Network for Cancer Subtype Analysis

XOmiVAE: an interpretable deep learning model for cancer classification using high-dimensional omics data

AVBAE-MODFR: A novel deep learning framework of embedding and feature selection on multi-omics data for pan-cancer classification

Autoencoders with shared and specific embeddings for multi-omics data integration

The prediction of drug sensitivity by multi-omics fusion reveals the heterogeneity of drug response in pan-cancer

Multi-Modal Evolutionary Deep Learning Model for Ovarian Cancer Diagnosis

Integration of Multimodal Data from Disparate Sources for Identifying Disease Subtypes

Accurate Tumor Subtype Detection with Raman Spectroscopy via Variational Autoencoder and Machine Learning

Performance Comparison of Deep Learning Autoencoders for Cancer Subtype Detection Using Multi-Omics Data

Multimodal Disentangled Variational Autoencoder With Game Theoretic Interpretability for Glioma Grading

A Multi-Omics Supervised Autoencoder for Pan-Cancer Clinical Outcome Endpoints Prediction

Benchmarking variational AutoEncoders on cancer transcriptomics data

InVA: Integrative Variational Autoencoder for Harmonization of Multi-modal Neuroimaging Data

Capturing the latent space of an Autoencoder for multi-omics integration and cancer subtyping